| 摘要 |
<p>Disclosed is an in vitro method for the identification of a patient responsive to or sensitive to the addition of bevacizumab treatment to a chemotherapy regimen, said method comprising determining the protein expression level of VEGFA and/or VEGFR2 in a sample from a patient suspected to suffer from or being prone to suffer from breast cancer, whereby an increased expression level of VEGFA and/or VEGFR2 relative to control expression levels determined in patients suffering from breast cancer is indicative of a sensitivity of the patient to the addition of bevacizumab to said chemotherapy regimen. Also disclosed is the use of bevacizumab for the preparation of a medicament for improving the progression free survival effect of a chemotherapy regimen of a patient suffering from breast cancer, wherein the protein expression level of VEGFA and/or VEGFR2 has been determined in a sample from said patient, and wherein the patient has an increased expression level of VEGFA and/or VEGFR2 relative to control expression levels determined in patients diagnosed with breast cancer, wherein the bevacizumab is to be administered to the patient in combination with the chemotherapy regimen.</p> |
